LymphoCide Y-90 (epratuzumab Y-90)

The patients who achieved an ongoing complete response (CR) did not receive further therapy; for patients who retained a partial response (PR) or no response (NR) until m CD19 CAR T cells became undetectable in PB by flow cytometry (FCM), the second hCD22 CAR T-cell infusion was initiated so that it did not prematurely interfere with the antitumor effect of m CD19 CAR T cells, and could prevent disease progression in the setting of continuous m CD19 CAR T-cell contraction; and for patients who had progressive disease (PD) or relapsed disease (RD) after responding to m CD19 CAR T cells, considering that the tumor had already produced immune escape from m CD19 CAR T cells, regardless of whether there were m CD19 CAR T cells detectable in PB by FCM, the second hCD22 CAR T-cell infusion was immediately initiated. CONCLUSION S equential CAR T-cell therapy may result in a durable response and is safe in pediatric r/r Burkitt lymphoma. Patients with secondary CNS involvement may benefit from s equential CAR T-cell therapy.

P1/2, N=0, Withdrawn, Immunomedics, Inc. | N=70 --> 0 | Active, not recruiting --> Withdrawn